The Journal of Practical Medicine >
Study on the effects of different dialysis modes on serum dp⁃ucMGP levels and lipid distribution in patients and their correlation with vascular calcification
Received date: 2025-08-25
Online published: 2025-11-26
Objective To investigate the effects of different dialysis modalities on serum levels of dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP), lipid profiles, and vascular calcification in maintenance hemodialysis (MHD) patients, and to identify the risk factors associated with vascular calcification in this population. Methods A total of 87 MHD patients admitted to the hospital between January 2019 and December 2022 were enrolled as study participants. Based on their dialysis modalities, they were categorized into three groups: the hemodialysis (HD) group, the HD combined with hemodiafiltration (HD + HDF) group, and the HD, HDF combined with hemoperfusion (HD + HDF + HP) group, with 29 patients in each group. The serum dp-ucMGP levels, lipid profiles, and extent of vascular calcification were compared across the three groups. Patients were divided into a vascular calcification group and a non-vascular calcification group based on the presence or absence of vascular calcification. Univariate analyses and multivariate analysis were performed to identify factors potentially associated with vascular calcification in patients undergoing MHD. Results The results demonstrated that the levels of blood phosphorus, intact parathyroid hormone (iPTH), serum dp-ucMGP, total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly higher in the HD group compared to the HD + HDF and HD + HDF + HP groups. Conversely, high-density lipoprotein cholesterol (HDL-C) levels were significantly lower in the HD group than in the other two groups, and all differences were statistically significant (P < 0.05). The levels of blood phosphorus, iPTH, and serum dp-ucMGP in the HD + HDF group were significantly higher than those in the HD + HDF + HP group, with statistically significant differences (P < 0.05). Compared with the HD group, the vascular calcification rate in the HD + HDF + HP group was significantly lower (P < 0.05). In comparison to the non-vascular calcification group, the vascular calcification group exhibited significant increases in MHD dialysis duration, age, pulse pressure, blood phosphorus, blood calcium, iPTH, LDL-C, TC, and dp-ucMGP (P < 0.05). Binary logistic regression analysis revealed that dialysis vintage, age, serum phosphorus, calcium, iPTH, and serum dp-ucMGP levels were independently associated with a higher risk of vascular calcification in MHD patients (P < 0.05). Conclusions Compared with the simple HD or HD + HDF dialysis modalities, the HD + HDF + HP regimen is associated with lower levels of serum phosphorus, iPTH, dp-ucMGP, lipids, and vascular calcification prevalence in MHD patients. However, dialysis modality itself was not an independent predictor of vascular calcification. Instead, factors such as dialysis vintage, age, serum phosphorus, calcium, iPTH, and dp-ucMGP were independently associated with vascular calcification in this population.
Tingting SUN , Mingai SONG , Jianfeng LI . Study on the effects of different dialysis modes on serum dp⁃ucMGP levels and lipid distribution in patients and their correlation with vascular calcification[J]. The Journal of Practical Medicine, 2025 , 41(22) : 3566 -3571 . DOI: 10.3969/j.issn.1006-5725.2025.22.014
| [1] | PATEL N, YAQOOB M M, AKSENTIJEVIC D, et al. Cardiac metabolic remodelling in chronic kidney disease[J]. Nat Rev Nephrol, 2022, 18(8): 524-537. doi:10.1038/s41581-022-00576-x |
| [2] | 陈如萍, 刘蕊, 孙遨, 等. 基于社区老年健康体检人群的慢性肾脏病流行病学调查[J]. 实用医学杂志, 2021, 37(13): 1755-1760. |
| [3] | CUI X, JIANG S, LIU L, et al. Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia[J]. Afr Health Sci, 2022,22(2): 362-368. doi:10.4314/ahs.v22i2.41 |
| [4] | KERYAKOS H K H, OKAILY N I, BOULIS M A Y, et al. Osteocalcin and vascular calcification in hemodialysis patients: An observational cohort study[J]. Int Urol Nephrol, 2021, 53(5): 1015-1023. doi:10.1007/s11255-020-02753-y |
| [5] | KHAMIS S S A, TAWFEEK A R, AL-HELBAWY M G A D, et al. Predictors of vascular calcification in hemodialysis patients[J]. Open J Nephrol, 2021, 11(2): 273-280. doi:10.4236/ojneph.2021.112022 |
| [6] | MAO L, HUANG H, ZHOU M, et al. Correlation between circulating dephosphorylated uncarboxylated matrix Gla protein and vascular calcification in peritoneal dialysis patients[J]. Int J Artif Organs, 2024, 47(12):885-893. doi:10.1177/03913988241293980 |
| [7] | DAI N, DIAO Z, HUANG H, et al. Disturbed carnitine metabolism is independently correlated with sarcopenia and prognosis in patients on hemodialysis[J]. Clin Nutr, 2024, 43(9): 2019-2027. doi:10.1016/j.clnu.2024.07.019 |
| [8] | AHLMANN C, STRONACH L, WATERS K, et al. Hemodiafiltration for children with stage 5 chronic kidney disease: Technical aspects and outcomes[J]. Pediatr Nephrol, 2024, 39(9):2611-2626. doi:10.1007/s00467-024-06285-w |
| [9] | ROSE M, FISCHER F, HOCKHAM C, et al. The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration[J]. Kidney Int, 2024, 106(5): 961-971. doi:10.1016/j.kint.2024.07.014 |
| [10] | YAO Z, WANG P, FU Q, et al. Efficacy and safety of plasma exchange combined with hemoperfusion in the treatment of organophosphorus poisoning: A meta-analysis[J]. Blood Purif, 2023, 52(6): 578-590. doi:10.1159/000530117 |
| [11] | HUU D N, QUY Q D B, THU H N T, et al. A combination of hemodialysis with hemoperfusion helped to reduce the cardiovascular-related mortality rate after a 3-year follow-up: A pilot study in vietnam[J]. Blood Purif, 2021, 50(1):65-72. doi:10.1159/000507912 |
| [12] | MADUELL F, BROSETA J J. Hemodiafiltration (HDF) versus expanded hemodialysis (HDx)[J]. Semin Dial, 2022, 35(5): 436-439. doi:10.1111/sdi.13071 |
| [13] | WANG J, LUO Y, JI X, et al. Effects of different hemodialysis modalities combined with low-calcium dialysate on mineral metabolism and vascular calcification in maintenance hemodialysis patients with chronic kidney disease[J]. J Appl Biomed, 2024, 22(4):228-233. doi:10.32725/jab.2024.027 |
| [14] | LI N, CUI W, MU D, et al. Effects of roxadustat on thyroid hormone levels and blood lipid metabolism in patients undergoing hemodialysis: A retrospective study[J]. Int J Med Sci, 2024, 21(10): 1806-1813. doi:10.7150/ijms.97599 |
| [15] | SAITO T, MIZOBUCHI M, HAMADA T, et al. Tumoral calcinosis due to severe hyperphosphatemia and secondary hyperparathyroidism without vascular calcification in a hemodialysis patient[J]. Clin Nephrol, 2021, 95(3): 166-170. doi:10.5414/cn110201 |
| [16] | HUANG J, BAO L, PAN Y, et al. The predictive value of coronary artery calcification score combined with bone mineral density for the 2-year risk of cardiovascular events in maintenance hemodialysis patients[J]. Int Urol Nephrol, 2022, 54(4): 883-893. doi:10.1007/s11255-021-02961-0 |
| [17] | MARTINS M T S, MATOS C M, LOPES M B, et al. Vascular calcification by conventional X-ray and mortality in a cohort of predominantly African descent hemodialysis patients[J]. Int J Artif Organs, 2021, 44(5): 318-324. doi:10.1177/0391398820962805 |
| [18] | BAO W, HE L, ZHANG A. Compensatory elevated serum intermedin levels are associated with increased vascular calcification in hemodialysis patients[J]. Int Urol Nephrol, 2022, 54(11): 3001-3007. doi:10.1007/s11255-022-03240-2 |
| [19] | WEN W, IGNACIO P C, RITUVANTHIKAA S, et al. Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients-A systematic review and meta-analysis[J]. Nephrol Dial Transplant, 2023, 38(3): 733-745. doi:10.1093/ndt/gfac171 |
| [20] | LIN R A, HSIEH J J, HUANG C C, et al. Circulating osteocalcin fractions are associated with vascular calcification and mortality in chronic hemodialysis patients[J]. Calcif Tissue Int, 2023, 113(4): 416-425. doi:10.1007/s00223-023-01122-y |
| [21] | WERIDA R H, ABOU-MADAWY S, ABDELSALAM M, et al. Omega 3 fatty acids effect on the vascular calcification biomarkers fetuin A and osteoprotegerin in hemodialysis patients[J]. Clin Exp Med,2022,22(2):301-310. doi:10.1007/s10238-021-00740-w |
| [22] | SADIO?LU R E, üSTüNER E, ERGüN ?, et al. Warfarin is associated with the risk of vascular calcification in abdominal aorta in hemodialysis patients: A multicenter case-control study[J]. Turk J Med Sci, 2021, 51(5): 2607-2615. doi:10.3906/sag-2104-221 |
| [23] | KANEDA H, NISHIYAMA T, OWADA K, et al. Extended-Hours Hemodialysis Without Dietary Restrictions Reduces Risk of Vascular Calcification[J]. J Med Cases, 2025, 16(8): 300-308. doi:10.14740/jmc5146 |
| [24] | AKIYAMA K I, MORIYAMA T, HANAFUSA N, et al. Citric acid-based bicarbonate dialysate attenuates aortic arch calcification in maintenance hemodialysis patients: A retrospective observational study[J]. J Nephrol, 2023, 36(2): 367-376. doi:10.1007/s40620-022-01470-2 |
| [25] | HOLDEN R M, BOOTH S L, ZIMMERMAN D, et al. Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): A randomized, placebo-controlled multi-center, pilot trial[J]. Nephrol Dial Transplant, 2023, 38(3): 746-756. doi:10.1093/ndt/gfac191 |
/
| 〈 |
|
〉 |